Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000947871-25-000838
Filing Date
2025-09-02
Accepted
2025-09-02 21:48:37
Documents
1
Period of Report
2025-08-25

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 3779
  Complete submission text file 0000947871-25-000838.txt   6520
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-39593 | Film No.: 251287623

Mailing Address 500 W. 5TH STREET AUSTIN TX 78701
Business Address 500 W. 5TH STREET AUSTIN TX 78701 512-900-4690
Shattuck Labs, Inc. (Issuer) CIK: 0001680367 (see all company filings)

EIN.: 812575858 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
OrbiMed Genesis GP LLC (Reporting) CIK: 0001808744 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39593 | Film No.: 251287621

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP IX LLC (Reporting) CIK: 0001920574 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39593 | Film No.: 251287622